Research programme: Mucopolysaccharidosis IIID therapeutics - Phoenix Nest/The Lundquist Institute/Washington University
Latest Information Update: 28 Dec 2022
At a glance
- Originator Phoenix Nest; Washington University
- Class Acetylglucosaminidases; Enzymes; Recombinant proteins
- Mechanism of Action Alpha N acetyl D glucosaminidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mucopolysaccharidosis III
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Mucopolysaccharidosis-III in USA
- 07 Nov 2018 Phoenix Nest receives SBIR grant from The National Institute of Neurological Disorders and Stroke for development in Mucopolysaccharidosis IIID
- 07 Nov 2018 Early research in Mucopolysaccharidosis III in USA (unspecified route)